What is the current price of Exelixis stock?

The current price of Exelixis on the XETRA Exchange is €32.28 as of the latest trading session in Germany. Refer to realtime updates on platforms like Meyka AI for current data.

Why was Exelixis considered a top loser recently?

Exelixis experienced a drop due to market volatility and sector-specific pressures, with its price decreasing in the short term compared to its previous highs.

What are the growth prospects for Exelixis?

Exelixis holds a positive long-term growth outlook with projections reaching €38.74 in a year, based on current product pipelines and strategic collaborations.

How does Meyka AI rate Exelixis?

Meyka AI assigns Exelixis a "B+" grade, considering factors like financial metrics, sector comparison, and future forecasts, suggesting a buy rating for interested investors.

What are Exelixis' main products?

Exelixis focuses on oncology treatments, particularly CABOMETYX and COMETRIQ, which are designed for advanced renal cell carcinoma and medullary thyroid cancer, respectively.

DE Stocks

Exelixis (EX9.DE) Stock Analysis: Navigating Challenges with Resilience

ByHuzaifa Zahoor December 7, 2025December 7, 2025

Exelixis, Inc. (EX9.DE) has experienced significant fluctuations, with its current price at €32.28. Recently listed among Germany’s top losers, it’s critical to dissect the factors influencing this biotechnology stock’s performance on the XETRA Exchange.